Duffie Ashley B purchased $27K of CE

Duffie Ashley B (SVP & GC) purchased 600 shares of Celanese Corp (CE) at $45.60 on 2026-08-11.

Original reporting
SEC EDGAR · Duffie Ashley B
Published Aug 13, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CE
Bullish
medium confidence
Mentioned
$CE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CEBullishLow
01

Why it matters

The newest fact is the open-market purchase of 600 shares at $45.60, totaling $27,360, with holdings after the trade of 31,925 shares.

02

Market read

Traders may note the insider buy as a minor sentiment input, but there is no accompanying operational or financial update in the text.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context like prior buys/sells or option exercises.

Relevance 4/10Novelty 5/10Timing: Form 4 filed 2026-08-13, covering an 2026-08-11 purchase.

Background

The article is a SEC Form 4 insider transaction disclosure for Celanese Corp, reported by SVP and General Counsel Duffie Ashley B.

Company-level read

Ticker impact

$CEBullishMedium confidence
Context

Celanese insider Duffie Ashley B bought 600 shares at $45.60 on 2026-08-11, disclosed via Form 4 filed 2026-08-13.

Expected impact

Limited near-term impact; any effect is likely short-lived unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction size ($27.36k) is modest and there is no 10b5-1 plan or other accompanying corporate event in the text.

Market effects

No sector-level implications are provided; this is company-specific insider activity only.

None indicated; the disclosure is not tied to regional demand or policy.

None indicated; no international operations or global catalyst is mentioned.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or pre-planned behavior, so the signal may be weaker than it appears.

Key entities

  • Celanese Corp

    US-listed company (CE) whose insider transaction is disclosed.

  • Duffie Ashley B

    SVP and General Counsel who reported the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CEMed

BMO raises Celanese stock price target to $58 on cost cuts

BMO Capital increased its price target for Celanese (NYSE:CE) to $58 from $56, citing cost-cutting and cash generation. The firm expects higher estimates for 2027-2028 due to growth in engineered materials, despite challenges in the acetyl chain business. Celanese reported Q3 2026 earnings of $1.65 per share, beating estimates, but revenue fell short. Other analysts have also raised price targets.

$CEMed

Celanese Corp (CE) Q3 2026 Earnings Call Highlights: 2027 Free Cash Flow Outlook

Celanese Corp (CE) reported Q3 2026 earnings, with CFO Chuck Kyrish highlighting $70M in cost savings this year and $30M-$40M expected in 2027. CEO Scott Richardson noted strong demand from AI data center build-outs driving growth in electronics. Q4 guidance includes a 6-7% volume decline in Engineered Materials and a $25M decline in acetyls. The company expects margin compression in Q4 due to methanol prices and other cost pressures.

$CEMedAI 8/10

Celanese Q3 Earnings Call Highlights

Celanese (NYSE: CE) expects restructuring costs to decrease by $30M-$40M in 2027 and additional cost savings of $30M-$40M in 2027. The company targets $150M in productivity improvements to offset inflation. Engineered Materials segment sees growth in electronics and healthcare, while automotive and nylon conditions remain mixed. Acetyl Chain faces margin compression due to outages and cost pressures.

$CEMed

Celanese (CE) Q3 2026 Earnings Call Transcript

Celanese (CE) reported Q3 2026 earnings, highlighting $100M in cost savings for 2027 and $700M-$800M in free cash flow. The company expects growth in electronics and healthcare segments to continue into 2027, while addressing potential capacity needs in downstream derivatives. Management discussed market dynamics in Asia and the impact of tariff changes on VAM. According to the company, they remain focused on productivity and targeted investments.

$CEMedAI 8/10

Celanese Q3 2026 slides: specialty focus drives margin gains

Celanese (NYSE:CE) reported Q3 2026 earnings with revenue of $2.56B, missing estimates, but EPS of $1.65 beat expectations. The company highlighted strong free cash flow of $461M and raised full-year guidance to $750M-$800M. Shares rose 3.86% to $49.79. Celanese is shifting focus to high-margin specialty applications in medical and electronics, driving margin expansion.

$CEHighAI 8/10

Why is Celanese stock rallying today?

Celanese (CE) stock rose 4.3% in pre-market trading after reporting Q3 adjusted EPS of $1.65, beating estimates. Revenue grew 6% YoY to $2.56B, missing slightly. The company raised its full-year 2026 EPS guidance to $6.00–$6.25. Analysts Mizuho and BofA increased price targets. The S&P 500 and NASDAQ showed mild gains.